Castle Biosciences, Inc. (NASDAQ:CSTL) Short Interest Up 5.3% in December

Castle Biosciences, Inc. (NASDAQ:CSTLGet Rating) was the recipient of a significant increase in short interest in the month of December. As of December 30th, there was short interest totalling 1,190,000 shares, an increase of 5.3% from the December 15th total of 1,130,000 shares. Based on an average trading volume of 200,900 shares, the short-interest ratio is currently 5.9 days. Currently, 4.9% of the company’s shares are sold short.

Insider Buying and Selling at Castle Biosciences

In other Castle Biosciences news, insider Derek J. Maetzold sold 3,833 shares of the business’s stock in a transaction dated Monday, December 5th. The stock was sold at an average price of $24.79, for a total value of $95,020.07. Following the completion of the transaction, the insider now directly owns 294,723 shares of the company’s stock, valued at $7,306,183.17. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, Director Daniel Bradbury sold 7,704 shares of the business’s stock in a transaction dated Tuesday, January 3rd. The stock was sold at an average price of $22.89, for a total value of $176,344.56. Following the sale, the director now directly owns 199,539 shares in the company, valued at $4,567,447.71. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Derek J. Maetzold sold 3,833 shares of the business’s stock in a transaction dated Monday, December 5th. The shares were sold at an average price of $24.79, for a total value of $95,020.07. Following the completion of the sale, the insider now owns 294,723 shares in the company, valued at $7,306,183.17. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 22,072 shares of company stock valued at $507,358. Company insiders own 7.30% of the company’s stock.

Institutional Trading of Castle Biosciences

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Millennium Management LLC increased its position in Castle Biosciences by 230.9% during the second quarter. Millennium Management LLC now owns 902,089 shares of the company’s stock worth $19,801,000 after buying an additional 629,448 shares during the last quarter. Bellevue Group AG acquired a new position in Castle Biosciences during the first quarter worth approximately $27,258,000. Citadel Advisors LLC increased its position in Castle Biosciences by 237.2% during the second quarter. Citadel Advisors LLC now owns 630,596 shares of the company’s stock worth $13,841,000 after buying an additional 443,589 shares during the last quarter. Wasatch Advisors Inc. increased its position in Castle Biosciences by 10.5% during the first quarter. Wasatch Advisors Inc. now owns 3,443,847 shares of the company’s stock worth $154,491,000 after buying an additional 327,359 shares during the last quarter. Finally, Essex Investment Management Co. LLC increased its position in Castle Biosciences by 256.3% during the second quarter. Essex Investment Management Co. LLC now owns 417,795 shares of the company’s stock worth $9,171,000 after buying an additional 300,550 shares during the last quarter. Institutional investors own 82.43% of the company’s stock.

Castle Biosciences Stock Performance

CSTL traded down $0.12 on Tuesday, hitting $26.88. 11,341 shares of the company were exchanged, compared to its average volume of 135,316. Castle Biosciences has a 12 month low of $15.58 and a 12 month high of $48.40. The stock’s fifty day moving average is $23.59 and its 200-day moving average is $25.60.

Castle Biosciences (NASDAQ:CSTLGet Rating) last released its earnings results on Wednesday, November 2nd. The company reported ($0.77) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.70) by ($0.07). Castle Biosciences had a negative return on equity of 11.87% and a negative net margin of 42.79%. The company had revenue of $37.01 million for the quarter, compared to the consensus estimate of $34.36 million. As a group, sell-side analysts expect that Castle Biosciences will post -2.92 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. Scotiabank assumed coverage on Castle Biosciences in a report on Wednesday, January 4th. They issued a “sector outperform” rating and a $54.00 price target on the stock. Robert W. Baird cut their price target on Castle Biosciences from $48.00 to $41.00 and set an “outperform” rating on the stock in a report on Thursday, November 3rd. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $57.14.

Castle Biosciences Company Profile

(Get Rating)

Castle Biosciences, Inc, a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma.

See Also

Receive News & Ratings for Castle Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Castle Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.